CoChat
Sign Up
Cited by 109

The DOI matches its Crossref record.

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Rutherford, Andrew I, Subesinghe, Sujith, Hyrich, Kimme L, Galloway, James B·2018·Annals of the Rheumatic Diseases
DOI 10.1136/annrheumdis-2017-212825
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2017-212825

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 19

  1. Subesinghe, 2016, A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK, BMC Musculoskelet Disord, 17, 322, 10.1186/s12891-016-1187-4 · DOI
  2. Lacaille, 2008, Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis, Arthritis Rheum, 59, 1074, 10.1002/art.23913 · DOI
  3. Dixon, 2011, The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses, Arthritis Res Ther, 13, R139, 10.1186/ar3453 · DOI
  4. Curtis, 2007, Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists, Arthritis Rheum, 56, 1125, 10.1002/art.22504 · DOI
  5. Galloway, 2011, Rheumatology, 50, 124, 10.1093/rheumatology/keq242 · DOI
  6. Askling, 2007, Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists, Ann Rheum Dis, 66, 1339, 10.1136/ard.2006.062760 · DOI
  7. Singh, 2011, Adverse effects of biologics: a network meta-analysis and Cochrane overview, Cochrane Database Syst Rev, 2
  8. Listing, 2005, Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis Rheum, 52, 3403, 10.1002/art.21386 · DOI
  9. Sakai, 2015, Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry, Arthritis Res Ther, 17, 74, 10.1186/s13075-015-0583-8 · DOI
  10. Watson, 2005, The British Society for rheumatology biologics register, Ann Rheum Dis, 64, iv42, 10.1136/ard.2005.042499 · DOI
  11. Vallejo, 2017, SAT0099 Polypharmacy is associated with an increased risk of adverse outcomes in patients with rheumatoid arthritis, Annals of the rheumatic diseases, 76, 806, 10.1136/annrheumdis-2017-eular.2262 · DOI
  12. Curtis, 2014, Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis, Arthritis Care Res, 66, 990, 10.1002/acr.22281 · DOI
  13. Zink, 2014, Evaluation of the RABBIT Risk score for serious infections, Ann Rheum Dis, 73, 1673, 10.1136/annrheumdis-2013-203341 · DOI
  14. Gabay, 2013, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial, Lancet, 381, 1541, 10.1016/S0140-6736(13)60250-0 · DOI · Paper page
  15. Smolen, 2016, Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study, Lancet, 388, 2763, 10.1016/S0140-6736(16)31651-8 · DOI
  16. Richter, 2016, Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis, Ann Rheum Dis, 75, 1667, 10.1136/annrheumdis-2015-207838 · DOI
  17. Abraham, 1995, Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group, JAMA, 273, 934, 10.1001/jama.1995.03520360048038 · DOI
  18. Abraham, 1998, Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group, Lancet, 351, 929, 10.1016/S0140-6736(05)60602-2 · DOI
  19. Qiu, 2013, Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis, Crit Care Med, 41, 2419, 10.1097/CCM.0b013e3182982add · DOI

Cited by

Sorted by citations

See all 109

Metadata

Authors
Rutherford, A. I., Subesinghe, S., Hyrich, K. L., & Galloway, J. B.
ORCID
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2018-06
Volume
77
Issue
6
Pages
905-910
ISSN
0003-4967
DOI
10.1136/annrheumdis-2017-212825
Cited by
109
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2017-212825
The paper
Rutherford, A. I., Subesinghe, S., Hyrich, K. L., & Galloway, J. B. (2018). Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2017-212825